Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bionovo randomizes first patient in phase III trial of Menerba

Nov. 18, 2011

Arcarios receives grant for development of drugs that promote bone growth

Nov. 18, 2011

BioSante Pharmaceuticals reports results from LibiGel pharmacokinetic study

Nov. 17, 2011

Prosidion researchers prepare novel GPR119 receptor agonists/DPP IV inhibitors

Nov. 17, 2011

Midatech obtains Swiss approval to test insulin-coated gold nanoparticles

Nov. 17, 2011

Promising results emerge from phase I/IIa Glymera study

Nov. 16, 2011

Researchers at Roche prepare new HSL inhibitors

Nov. 16, 2011

New GPR119 agonists/DPP IV inhibitors claimed

Nov. 16, 2011

Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone

Nov. 15, 2011

Novartis reports first data from 3-year phase III SMC-021 study

Nov. 15, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...